Skip to main content

Table 1 Baseline characteristics of study patients

From: Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial

  TACE + Sorafenib TACE + Placebo
  n = 24 n = 26
Age (years) median (min-max) 58.5 (44.0-66.0) 58.0 (43.0-69.0)
BMI (kg/m2) median (min-max) 27.5 (20.2-40.6) 26.3 (21.0-37.9)
Biopsy proven n (%)     
 yes 8 (33.3%) 6 (23.1%)
 no 16 (66.7%) 20 (76.9%)
Child pugh stage n (%)     
 A 14 (58.3%) 20 (76.9%)
 B 9 (37.5%) 6 (23.1%)
 C 1 (4.2%) -  
Karnofsky index n (%)     
 80 6 (25.0%) 4 (15.4%)
 90 10 (41.6%) 16 (61.5%)
 100 8 (33.3%) 6 (23.1%)
Underlying liver disease n (%)     
 Viral hepatitis     
  B 3 (12.5%) 3 (11.5%)
  C 11 (45.8%) 7 (26.9%)
 alcoholic 7 (29.1%) 11 (42.3%)
 other 3 (12.5%) 5 (19.2%)
MELD score at listing median (min-max)     
 labMELD score 11 (6–15) 11 (6–37)
 exceptional MELD score 27.5 (27.5-40.1) 25.2 (21.9-40.1)
AFP (IU/ml) median (min-max)     
 start of study 13.2 (1.2 – 2.961) 9.8 (1.3 – 225)
 end of study 6.2 (1.0 – 1.788) 9.4 (2.0 – 362)